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Available online 16 June 2016While no deﬁnitive cure for Alzheimer's disease exists yet, currently available treatments would beneﬁt greatly
from an earlier diagnosis. It has previously been shown that Magnetization transfer contrast (MTC) imaging is
able to detect amyloid β plaques in old APP/PS1 mice. In the current study we investigated if MTC is also able
to visualize early amyloid β (Aβ) induced pathological changes. In a cross-sectional study, a comparison was
made between theMT ratio of wild type (WT) and APP/PS1mice at 2, 4, 6, 8 and 24months of age.We observed
an increased MT-ratio in the cortex of 24 month old APP/PS1 mice as compared to WT mice. However, when
comparing the MT-ratio of the cortex of WT mice with the MT-ratio of the APP/PS1 mice at 2, 4, 6 or 8 months
of age, no signiﬁcant changes could be observed. In contrast to the cortex, we consistently observed a decreased
MT-ratio in the spleniumof 4, 6 and 8month old APP/PS1mice as compared to age-matchedWTmice. Lastly, the
decreased MT-ratio in the splenium of APP/PS1 mice correlated to the Aβ plaque deposition, astrogliosis and
microgliosis. ThisMT-ratio decrease did however not correlate to themyelin content. Combined, our results sug-
gest that MTC is able to visualize early Aβ-induced changes in the splenium but not the cortex of APP/PS1 mice.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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APP/PS11. Introduction
Alzheimer's Disease (AD) is a devastating neurological disorder and
the most common causes of dementia in the western world. Pathologi-
cally, AD is characterized by prominent amyloidosis and the formation
of neuroﬁbrillary tangles which eventually result in neurodegeneration
and brain atrophy (Querfurth and LaFerla, 2010). However, establishing
an AD diagnosis in the clinic is difﬁcult and while a deﬁnite diagnosis of
AD is only possible by post-mortem histological validation, a combina-
tion of different tests may allow for a deﬁnite AD diagnosis. One of the
most commonly used techniques to aid in diagnosing AD is the assess-
ment of hippocampal atrophy via the acquisition of anatomical magnet-
ic resonance (MR) images (Fox et al., 1996). However, this has the
disadvantage that the pathology of the disease must have already
progressed towards the late stages, when hippocampal atrophy occurs.
Unfortunately, the clinical manifestations of AD are preceded by the ini-
tial pathology by decades (Jack et al., 2009). As this offers a large
therapeutical window, there is an urgent need for means to diagnose
AD during this period when pathology is present but no behavioral
and cognitive symptoms can be observed yet.of Antwerp, Campus Drie Eiken
k), Belgium.
. This is an open access article underMagnetization transfer contrast (MTC) imaging is an MR technique
currently being explored as a new option to visualize amyloidosis. Con-
ventional MRI techniques are only able to visualize highly mobile pro-
tons possessing a sufﬁciently long T2 relaxation time, making it
impossible to visualize the less mobile, macromolecule-bound protons
(like those trapped within amyloid β plaques). MTC however, applies
an off-resonance saturation pulse which selectively saturates the mac-
romolecular spinswhile excluding themobile spins. Asmacromolecular
and mobile spins are coupled, the saturation of the macromolecular
spins inﬂuences the mobile spin state via exchange processes. This re-
sults in a decrease of the measurable net magnetization of the mobile
spins. The latter reﬂects themacromolecular environment, i.e. magneti-
zation transfer contrast (Henkelman et al., 2001).
Until recently, MTC has mainly been used to visualize white matter
lesions in Multiple Sclerosis patients. As protons within the myelin
sheaths are less mobile, changes in themagnetization transfer (MT) ra-
tios reﬂect changes in themyelin content (Dousset et al., 1992; Rovira et
al., 1999; Rovira and Leon, 2008, Rausch et al., 2009). In AD patients
however, MTC is often used as an addition to the determination of hip-
pocampal atrophy rather than a standalone test. As such, a reduction in
grey matter MT-ratio is often observed in AD and MCI patients (Kabani
et al., 2002; van der Flier et al., 2002; Ridha et al., 2007a,b; Kiefer et al.,
2009; Fornari et al., 2012; Giulietti et al., 2012; Ropele et al., 2012).
While several studies report on the use of MTC in a clinical setting, thethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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interesting ﬁeld of study as it would allow to untangle the pathological
changes underlying the observed differences in MT-ratios. For this rea-
son, we have previously performed a proof of concept study in old mice
in which we have investigated the ability of MTC to detect amyloidosis
in vivo, using 2 different mouse models. By employing the BRI mouse
model and the APP/PS1 mouse model, we mimicked early and late
stage of amyloid pathology and noted an increased MT-ratio in cortical
regions which correlated well to the histologically determined amyloid
β (Aβ) plaque load (Bigot et al., 2014). In the current study, we validat-
ed the latter and built upon those ﬁndings by investigating the ability of
MTC to detect early Aβ-induced pathology in youngmice in vivo. In ad-
dition, we investigated how the observed changes in MT-ratio correlate
to different histological markers which reﬂect the different pathological
processes present due to amyloidosis.
2. Materials and methods
2.1. Animals & experimental groups
We used male wild type (WT) C57BL6/J mice (n = 61) and male
transgenic APPKM670/671NL/PS1L166P mice (n = 76, further referred to
as APP/PS1 mice) (Radde et al., 2006). Mice were divided in 5 different
groups according to age (2, 4, 6, 8 and 24 months) as shown in Fig. 1.A.
Micewere housed in the animal housing facility of theUniversity of Ant-
werp during the entire experiment. During the experiment, mice were
kept in a normal day-night cycle (12/12) with ad libitum access to
food and water. All experimental procedures were performed in accor-
dance with European guidelines (2010/63/EU) and were approved by
the Ethics Committee for Animal Experiments of the University of Ant-
werp (approval n. 2012-46).
2.2. MRI
At 2, 4, 6 and 8 months of age, mice were subjected to 1H MRI scan-
ning performed using a 7T PharmascanMR scanner (Bruker, Germany).
This system is equipped with a standard Bruker crosscoil setup which
uses a quadrature volume coil for excitation and array mouse surface
coil for signal detection. The system was interfaced to a Linux PC run-
ning Topspin 2.0 and Paravision 5.1 software (Bruker Biospin). Anesthe-
sia was induced using 2% isoﬂurane (Forane Abbott, UK) in a gas
mixture of 30% O2 and 70% N2 at a ﬂow rate of 600 ml/min. DuringFig. 1. Setup of the experiment andMTC analyses. Panel A shows the 5 different age groups used
location of the anterior (Slice 1) and posterior slide (Slice 2) chosen for MTC acquisitions and an
slices.MR acquisition, isoﬂurane concentration was maintained at 1.5% and
mice respiration rate was constantly monitored using a pressure sensi-
tive pad. In addition, mice body temperature wasmonitored via a rectal
probe andwas held constant at 37.0± 0.3 °C usingwarm air coupled to
a feedback unit (SA instruments, NY, USA). Both respiration and body
temperature control systems were controlled by pcSam monitoring
software (SA instruments, NY, USA). To ensure a uniform slice position-
ing, we ﬁrst acquired coronal, horizontal and sagittal multi-slice rapid
acquisition and relaxation enhancement (RARE) images using the fol-
lowing parameters: repetition time (TR) = 2500 ms, echo time
(TE) = 33 ms, matrix size 256 × 256, ﬁeld of view (FOV) =
(20 × 20) mm2, 8 slices, slice thickness = 0.8 mm, RARE factor = 8.
We then chose 2 coronal slice positions (cfr. Fig. 1.B) in the brain to ac-
quireMTC in an axial direction. MTC was acquired using a Spin Echo se-
quence (TE= 33.0ms, TR= 3000ms, matrix size= 256 × 256, ﬁeld of
view= (20 × 20)mm2, 2 slices, slice thickness= 1mm, number of av-
erages = 1). RARE images were acquired without applying an off-reso-
nance RF pulse (unsaturated) and with an off-resonance RF pulse
(saturated) at an offset frequency of −16,875 Hz (pulse strength =
12 μT, number of pulses = 36, pulse length = 40 ms, saturation
time = 1440 ms).
2.3. MRI analysis
From the images acquired with and without the off-resonance RF
pulse, the MT-ratio maps were calculated by calculating the voxel
wise ratio of the signal intensities= (unsaturated− saturated) / unsat-
urated. Within Amira (v5.4.0), regions of interest (ROIs, cfr. Fig. 1.C)
were delineated on the MTC images (offset frequency of−16,875 Hz),
and the regional mean MT-ratios were extracted. Within the posterior
slice we delineated the cortex, the caudate putamen, the septal area
and the genu of the corpus callosum.Within the anterior slice, we delin-
eated the cortex, the hippocampus, the thalamus, the hypothalamus,
the amygdala and the splenium of the corpus callosum.
2.4. Histology
For histological examination,micewere sacriﬁced bymeans of cervi-
cal dislocation. The complete brainwas dissected and ﬁxed in Fade4 ﬁx-
ative. Fixed brains were sent to HistoGeneX (Antwerp, Belgium) where
parafﬁn sectionsweremade of the left brain hemisphere (5 μm). Immu-
nohistochemical (IHC) staining for Aβ plaques was done as follows:in this experiment and the number ofWT and APP/PS1mice per group. Panel B shows the
alysis. Panel C shows the different regions of interest chosen on the anterior and posterior
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followed by oxalic acid for 1min. Slides were then pre-treated in formic
acid for 10 min to quench endogenous peroxidase activity. After
quenching the endogenous peroxidase activity, the slides were incubat-
ed for 15 min at room temperature with a mouse anti-amyloid beta an-
tibody (clone 4G8, 1/20000, Eurogentec, SIG-39200). Next, slides were
incubated with a labeled polymer (Dako EnVision + System HRP-La-
beled Polymer Anti-Mouse, Dako, K4001). Finally, the substrate was vi-
sualized using the DAB chromogen (Dako Liquid DAB+ substrate
chromogen system, Dako) for 5 min. All steps were performed on the
automated Lab Vision Autostainer 480S (Thermo Scientiﬁc). In every
4G8 staining run, an IgG control antibody was included (mouse IgG2b,
Dako).
For Myelin Basic Protein (MBP) staining, epitope retrieval was per-
formed in Target Retrieval Solution (Dako) for 30 min at 97 °C. After
quenching the endogenous peroxidase activity, the slides were incubat-
ed for 30min at room temperature with amouse anti-myelin basic pro-
tein antibody (clone SMI-94, 1/5000, Covance Antibody Products, SMI-
94R). Next, slides were incubated with a labeled polymer (Dako
EnVision + System HRP-Labeled Polymer Anti-Mouse, Dako, K4001).
Finally, the substrate was visualized using the DAB chromogen for
5 min. All steps were performed on the automated Lab Vision
Autostainer 480S (Thermo Scientiﬁc). In every MBP staining run, an
IgG control antibody was included (mouse IgG1, Abcam).
For IBA1 IHC staining, epitope retrieval was performed in citrate
buffer (LabVision Corporation, pH 6) for 30 min at 97 °C. After
quenching the endogenous peroxidase activity, the slides were
incubated for 30 min at room temperature with a rabbit anti-Iba1 anti-
body (1/5000, Wako, #019-19741). Next, slides were incubated with a
labeled polymer (Dako EnVision + System HRP-Labeled Polymer
Anti-Rabbit, Dako, K4003). Finally, the substrate was visualized using
the DAB chromogen (Dako Liquid DAB+ substrate chromogen system,
Dako) for 5 min. All steps were performed on the automated Lab Vision
Autostainer 480S (Thermo Scientiﬁc). In every IBA-1 staining run, an
IgG control antibody was included (rabbit IgG, Dako).
For GFAP IHC stainings, epitope retrieval was performed using Cell
conditioning solution (Ventana). The slides were incubated for 28 min
at 37 °C with a rabbit anti-GFAP antibody (1/7500, Dako, Z0334).
Next, slides were incubated with an OmniMap anti-rabbit HRP detec-
tion system (Ventana). All steps were performed on the automated
Ventana Discovery® XT platform (Ventana). In every GFAP staining
run, an IgG control antibody was included (rabbit IgG, Dako). For all 4
stainings, stained slideswere scanned using theMirax digital slide scan-
ner (Carl Zeiss).
2.5. Histology quantiﬁcation
Quantiﬁcation of the histological slides was performed by DCI Labs
(Belgium). In short, the histological images are color deconvolved to
separate the colors on the stained slides (Ruifrok and Johnston, 2001).
This results in a grey value image of the MBP, GFAP, 4G8 and IBA1
stained slides. On these images hysteresis thresholding was applied to
segment the stained regions and to determine the % area positive for
the respective staining (% optical density, % O.D.). All analyseswere per-
formed with in house developed software using Openslide C interface
(Openslide.org) to read the MIRAX images.
2.6. Statistics
Statistical analysis was performed using SPSS statistics 20.0 (IBM
279 software). We ﬁrst performed a Levene's test to assure equal vari-
ance in the distribution of MT-ratio values of WT and APP/PS1 mice
across 2, 4, 6, and 8 months of age. Next, for each region, a two-way
ANOVA was performed to compare the MT-ratios of WT and APP/PS1
mice across the 4 timepoints, allowing us to investigate a possible geno-
type effect, a time effect or an interaction between time and genotype. ABonferroni correction was performed for the different ages and a
Bonferroni-corrected p b 0.05 was considered signiﬁcant. To compare
the MT-ratios of the 24 month old WT and APP/PS1 mice groups, a
two sided student's t-test was used. To correlate the MT-ratios to the
corresponding histology, the Spearman's rank correlation coefﬁcient
was calculated. In all cases, a p b 0.05 was considered signiﬁcant.
3. Results
3.1. MT-ratios are increased in the cortex of aged APP/PS1 mice
First, we validated our previous study in which we observed that
MT-ratios are increased in the cortex of elderly APP/PS1mice compared
toWTmice (Bigot et al., 2014). Thiswas due to the current study using a
shorter RARE sequence and a 7T MR system to acquire MTC images,
while the previous study used a longer PRESS sequence on a 9.4T MR
system. As such, we performed MTC imaging and quantiﬁcation as de-
scribed above on 10 WT and 9 APP/PS1 male mice at 24 months of
age. Fig. 2.A shows representative anterior and posterior brain MT-
ratio maps of WT and APP/PS1 mice. Next, we quantiﬁed the MT-ratios
in the different ROIs and observed a signiﬁcantly higher MT-ratio in
both the anterior and the posterior cortex of APP/PS1 mice when com-
pared to WT mice (p = 0.0017 and p = 0.0112 respectively, see Fig.
2.B). In addition, we observed a lower MT-ratio in the genu of the Cor-
pus Callosum of APP/PS1 mice when compared to WT mice (p =
0.0403), but not in the splenium of the Corpus Callosum.
3.2. MT-ratios changes in young APP/PS1 mice
Next, we investigated whether MTC is able to visualize early patho-
logical changes during progressive amyloidosis. In the APP/PS1 mouse
model, the initial plaque formation starts aroundweek 6 and progresses
to very severe amyloidosis bymonth 8 (Radde et al., 2006). As such, we
performedMTC imaging at 2, 4, 6 and 8months of age. In Fig. 3we show
representative MT-ratio maps of the anterior and posterior slide for
both WT and APP/PS1 mice, at these respective ages. Next, we quanti-
ﬁed these MT-ratio maps and the quantiﬁcation of the different grey
matter ROIs is shown in Fig. 4.A. Unexpectedly, within the anterior cor-
tex, the posterior cortex and the hippocampus we did not observe any
signiﬁcant differences in MT-ratio between WT and APP/PS1 mice at
any age. However, we observed a time effect in the anterior cortex
showed (p b 0.001), and a genotype effect in the hippocampus (p =
0.039). In contrast to these 3 ROIs, we did observe a signiﬁcantly higher
MT-ratio within the caudate putamen of APP/PS1 mice at 4 months of
age (but not at 6 or 9 months of age), compared to WT mice (p =
0.010). Additionally, within the caudate putamen we did not observe
a genotype effect but we observed a time effect (p = 0.005) and an in-
teraction between time and genotype (p = 0.043). Within the hypo-
thalamus we did observe a time effect (p = 0.048) and a lower MT-
ratio at 6 months of age in APP/PS1 mice when compared to WT mice
(p = 0.027). And lastly, within the thalamus we only observed a
lower MT-ratio in APP/PS1 mice as compared to WT mice at 8 months
of age (p = 0.039).
Besides these grey matter ROIs, we also quantiﬁed the MT-ratios of
the genu and splenium of the Corpus Callosum (Fig. 4.B). In both the
genu and splenium we observed a time effect (p = 0.002 and
p b 0.001 respectively) and a genotype effect (p = 0.019 and
p b 0.001 respectively). In the genu we observed a signiﬁcantly lower
MT-ratio between APP/PS1 mice and WT mice at 6 months of age
(p = 0.005). The most interesting ﬁnding, however, is a lower MT-
ratio in the splenium for APP/PS1 mice as compared to WT mice.
While the latter is not signiﬁcant at 2 months of age (p= 0.108), it be-
comes increasingly signiﬁcant from month 4 onwards (p = 0.009) and
persists at month 6 and month 8 of age (p = 0.005 and p = 0.010
respectively).
Fig. 2. Validation of the ability of MTC imaging to visualize amyloid pathology in very old APP/PS1mice. Panel A shows representativeMT-ratiomaps of the anterior and posterior slide of
24month oldWT and APP/PS1mice. The higher theMT-ratio, thewarmer the color on theMT-ratiomap (blue= lowMT-ratio, red=highMT-ratio). Panel B shows theMT-ratio in these
24 month old WT (blue dots) and APP/PS1 mice (red dots) in the anterior and posterior cortex as well as the genu and splenium of the corpus callosum. Indicated in black, we show the
average MT-ratio ± SEM and the statistical signiﬁcant differences between WT and APP/PS1 mice (*p b 0.05).
88 J. Praet et al. / NeuroImage: Clinical 12 (2016) 85–923.3. Changes in the Splenium MT-ratio correlate to amyloidosis and gliosis
As the decrease in MT-ratio in the splenium of APP/PS1 mice com-
pared to WT mice persisted longitudinally, we decided to focus ourFig. 3. Representative MT-ratio maps of the anterior and posterior slice of both WT and APP/PS
higher the MT-ratio, the warmer the color on the MT-ratio map (blue = low MT-ratio, red =histological analysis on this region to validate the underlying patholog-
ical causes of this decreasedMT-ratio. In the different panels of Fig. 5we
show images of representative immunohistochemical stainings of the
hippocampus and overlaying splenium (the latter is delineated by the1 mice. The rows indicate the different ages of the mice (2, 4, 6 and 8 months of age). The
high MT-ratio).
Fig. 4.MT-ratios of the anterior and posterior cortex, caudate putamen, hippocampus, hippothalamus and thalamus (panel A) and of 2whitematter regions, the genu and splenium of the
corpus callosum (panel B). The blue dots each time represent theMT-ratio of theWTmice while the red dots indicate theMT-ratios of the APP/PS1mice. Indicated in black, we show the
averageMT-ratio± SEM. Statistical signiﬁcant differences betweenWT and APP/PS1mice at a given time point are indicated in blackwhile statistically signiﬁcant group effects are shown
in green and time effects in blue (*p b 0.05, **p b 0.01, ***p b 0.001).
89J. Praet et al. / NeuroImage: Clinical 12 (2016) 85–92dotted line). The left column each time shows the images of the WT
mice while the right column shows the images of the APP/PS1 mice.
The rows indicate the different ages of the mice (2, 4, 6 and 8 months
old). Fig. 5.A shows the images of the 4G8 staining for amyloid β
plaques. It can be perceived that very few amyloidβ plaques are present
at 2 months but that amyloidosis has progressed severely by month 8.
Importantly, some amyloid β plaques can be noted in the splenium.
Fig. 5.B shows the images of the MBP staining (Myelin basic protein)
and while very few amyloid β plaques are present in the Splenium,
we could not observe any visual changes in myelination. Fig. 5.C and
Fig. 5.D show the GFAP and IBA-1 staining for astrocytes and microglia
respectively. It can be noted that microglia and astrocytes are present
in the splenium and the amount increases as amyloidosis progresses.
Next, we quantiﬁed these histological images of the spleniumby de-
termining the % O.D. of each staining for each animal separately, which
was then correlated to the correspondingMT-ratio of the respective an-
imals (Fig. 6). For the 4G8, GFAP and IBA-1 stainingwe found a clear cor-
relation between the % O.D. of the staining and the corresponding MT-
ratio (R = 0.564 with a p b 0.001, R = 0.517 with a p b 0.001 andR= 0.336with a p= 0.019 respectively). Unfortunately, no correlation
between the % O.D. MBP staining and the MT-ratio could be observed
(R = 0.016 with a p = 0.912). It should be noted, while we could ob-
serve an MT-ratio genotype effect in both the hippocampus and the
genu, we did not observe any signiﬁcant correlations between the MT-
ratios and the % O.D. of any of the 4 histological stainings for these 2
ROIs (data not shown).
4. Discussion
In this study, we investigated the possibility of usingMTC imaging to
detect early amyloid-driven changes in young APP/PS1 mice. We ob-
served a genotype effect in both the genu and splenium of the corpus
callosum while only the splenium showed an early but signiﬁcant MT-
ratio reduction in APP/PS1 mice compared to WT mice. The latter al-
ready is already visible at 2 months of age but is signiﬁcant from
4 months of age onwards. As the splenium is a very homogenously
structured part of the brain with many large macro-molecules in the
myelin sheath, even small disturbances might induce changes that can
Fig. 5.Representative images of the immunohistochemical staining for 4G8 (amyloidβ plaques, panel A), MBP (myelin, panel B), GFAP (astrocytes, panel C) and IBA-1 (microglia, panel D)
on sagittal brain slides. The left column each time shows the WT mice while the right column shows the APP/PS1 mice. The rows indicate the different ages of the mice (2, 4, 6 and
8 months). The splenium is delineated with a dotted black line (or a dotted white line in the case of the MBP staining).
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in the white matter structure. We observed that the splenium MT-
ratio correlated to the degree of Aβ plaque deposition (4G8) as well as
the accompanying astro- and microgliosis (GFAP and IBA-1 respective-
ly). Interestingly, no correlation was found between the lower MT-ratio
and % O.D. myelination (MBP). This is in concordance with another
study which also did not observe any correlation between MT-ratios
and myelination (Fjær et al., 2015). Of note, while MBP only reveals
white matter damage at a macroscopic level (e.g. profound demyelin-
ation), the myelin microstructure might have been altered signiﬁcantly
but investigation of the latter was beyond the scope of this work.
While we believe that Aβ-induced astro- and microgliosis are the
driving factors behind the observed MT-ratio changes (which is sup-
ported by the correlations we found), it is important to note that
other, still unknown factors could possibly also contribute to theobservedMT-ratio changes. As such,whilewe did not investigate the in-
volvement of peripheral immune cells like for example neutrophils, the
latter are known to migrate towards Aβ plaques where they cause ex-
tensive remodeling of the tissue (Baik et al., 2014). Secondly, the pres-
ence of vascular Aβ (Radde et al., 2006) and inﬂammation-induced
edema could potentially have a profound effect on tissue perfusion
and thus the pool of ‘free protons’whichwill affect theMT-ratio. Lastly,
it is known that extensive synaptic loss occurs very early in the APP/PS1
model which also causes extensive tissue remodeling (Bittner et al.,
2012). Via these 3 illustrative examples, we wish to stress the need for
further research to fully elucidate which pathological features are be-
hind the observed MT-ratio changes.
In contrast to what we expected, we could not observe changes in
the MT-ratio in cortical regions at any of the time points investigated.
While several regions (thalamus, hypothalamus and caudate putamen)
Fig. 6. Correlation of the % O.D. 4G8 (amyloid β plaques), GFAP (astrocytes), IBA-1 (microglia) andMBP (myelin) staining to the correspondingMT-ratio for eachmouse. The values of the
WT mice are shown as triangles while those of the APP/PS1 mice are shown as circles. The colors indicate the age of the mice with grey indicating 2 month old mice, green indicating
4 month old mice, blue indicating 6 month old mice and red indicating 8 month old mice. Shown are also the Spearman's rank correlation coefﬁcient R and the corresponding p-value.
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ences occurred only at 1 time point per region and did not persist longi-
tudinally. However, while the latter does not contradict our earlier
ﬁndings in very old APP/PS1 mice (Bigot et al., 2014), it does not
match with a recent study by Pérez-Torres et al. (Perez-Torres et al.,
2014). The latter study reported a higher MT-ratio during the early
pre-plaque phase in the cortex and hippocampus of Tg2576 mice as
compared to WT mice. Additionally, these authors also observed an in-
creased MT-ratio genotype effect in the hippocampus, which contrasts
the decreased MT-ratio genotype effect which we observed in the hip-
pocampus. Currently, we do not have an explanation for these contra-
dictory results. In their study, MTC images were acquired using a 9.4T
MR scanner and an off-resonance frequency pulse of 20 kHz, which is
only slightly lower than the 22.5 kHz which was used in our previous
study (Bigot et al., 2014), and thus only slightly different from the
recalculated - 16,875 Hz used on the 7T MR scanner in the current
study. While the APP/PS1 mouse model was used, a model which de-
velops Aβ plaques quicker (Radde et al., 2006), their study used the
Tg2576 mouse model which develops Aβ very slowly (Hsiao et al.,
1996). However, one would expect to see more changes as Aβ plaque
pathology ismore severe in the APP/PS1. As such, no deﬁnitive explana-
tion can be given for the discrepancy between both studies.
Asmentioned above, the current study builds upon our previous ob-
servations that MTC is able to pick up changes in the brain's cortical
structures in very old transgenic Alzheimer mice (APP/PS1 mice)
(Bigot et al., 2014). While the latter study was done using a 9.4 Tesla
MRI scanner and a multi echo sequence, the current study is performed
using a 7.0 TeslaMRI scanner and an RARE sequence. The previously op-
timized offset frequency pulse to detect Aβ plaques was recalculated for
this new acquisition setup and determined at 16,875 Hz. To exclude the
possibility that this change in acquisition setup is responsible for the in-
ability of MTC to detect early grey matter changes, we initially
reproduced the previous results using 24 month old APP/PS1 mice. It
was that the MT-ratio is higher in the cortex of old APP/PS1 micewhen compared to WT mice. Therefore, the change in MT acquisition
setup does not inﬂuence the observed differences between WT and
APP/PS1 mice. Notably, the MT-ratio values are higher in the current
study compared to the previous studywhichmay to bedue to thediffer-
ent acquisition setups used in the 2 studies.
Clinically, several studies have explored the use of MTC imaging as
an additional tool for the diagnosis of AD, but so far MTC imaging is
not yet routinely used. All of these studies observed a lower MT-ratio
(or MT derived parameters) in AD patients compared to healthy con-
trols. Among the regions investigated in these studies are the whole
brain, the hippocampus, the frontal and temporal lobe, the posterior
cingulate and parietal cortex, the putamen and the thalamus (van der
Flier et al., 2002; Ridha et al., 2007a,b; Kiefer et al., 2009; Giulietti et
al., 2012; Ropele et al., 2012). Interestingly, the change in overall MT-
ratio has been directly correlated to the decline in memory function,
motor skills and executive functions of AD patients (Seiler et al.,
2014). Additionally, several clinical MT imaging studies have observed
white matter changes in AD patients. As such, a lower MT-ratio was
noted in the white matter in general for AD patients (Kabani et al.,
2002) and in the splenium of AD patients (Hanyu et al., 1999). In addi-
tion, MTCwas also able to detect demyelination of the superﬁcial white
matter in the cuneus, para-hippocampal region and the superior tempo-
ral regions (Fornari et al., 2012). In our study, we also observed signiﬁ-
cantly reducedMT-ratios in the genu and spleniumof APP/PS1mice and
we observed a trend towards reduced MT-ratios in the grey matter re-
gions of APP/PS1mice (anterior cortex, posterior cortex and hippocam-
pus). As such, our results in young mice match with the outcome of the
clinical studies. However, in the current study and the previous study
(Bigot et al., 2014), we observed increased MT-ratios in 24 month old
APP/PS1mice.Whilewe donot have a solid explenation for this discrep-
ancy, it might be due to the fact that amyloidosis is very severe at
24 months of age in this model, but no tau pathology or neurodegener-
ation occurs (Radde et al., 2006). Of interest is also the time and geno-
type effect in the splenium which indicate that MTC might be useful
92 J. Praet et al. / NeuroImage: Clinical 12 (2016) 85–92to follow-up disease progression longtudinally. This time effect in the
splenium and the time effects whichwe observed in the anterior cortex,
the caudate putamen and the hypothalamus indicate that the brain's
microstructure still changes signiﬁcantly during the longitudinal fol-
low-up. In light of these ﬁndings it was recently shown that most
major structural changes in rodent brains are done by 3 months of
age, but that changes in myelination continue up until 6 months of
age (Hammelrath et al., 2015;Mengler et al., 2014). The latter highlights
a pitfall of our study, as amyloidosis in the APP/PS1 model is very ag-
gressive and starts already at 6 weeks of age, when the brain is not ma-
ture yet.
To summarize, we conﬁrmed the results of our previous study, in
which we observed a higher MT-ratio in the cortex of 24 months old
APP/PS1 mice. However, when studying younger ages, while Aβ plaque
deposition is ongoing, no notable and persistent differences between
WT andAPP/PS1mice in any greymatter regionwere observed.Howev-
er, in the splenium of the corpus callosum a genotype effect was noted.
In addition,we observed a reducedMT-ratio in the splenium of APP/PS1
mice at 4 months of age, which persisted up until 8 months of age. As
the latter correlated to Aβ plaque deposition, astro- and microgliosis,
we believe that changes in thewhitematter changes due to amyloidosis
might offer an interesting opportunity to identify early Aβ plaque
pathology.
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